Announcements Trials
Browse Landscape

Phase

Phase NA 2Phase 2 2Phase 3 1

Status

Recruiting 2Unknown 1Terminated 1Not yet recruiting 1Completed 1

Sponsor Class

OTHER 6INDUSTRY 3

Study Type

Interventional 5Observational 1

Sponsor

Cancer Type

Gastrointestinal 4Gynecologic 1

Conditions

Carcinoma, Hepatocellular 115Cholangiocarcinoma 24Carcinoma, Renal Cell 20Liver Neoplasms 12Stomach Neoplasms 10Biliary Tract Neoplasms 10Thyroid Neoplasms 8Endometrial Neoplasms 8Breast Neoplasms 8Neoplasms 7Recurrence 6Neuroendocrine Tumors 5Neoplasm Metastasis 5Melanoma 5Uterine Cervical Neoplasms 4Thyroid Carcinoma, Anaplastic 4Thyroid Cancer, Papillary 3Pancreatic Neoplasms 3Ovarian Neoplasms 3Liver Diseases 3Cirrhosis, Familial, with Pulmonary Hypertension 3Carcinoma, Adenoid Cystic 3Brain Neoplasms 3Advanced Biliary Tract Cancer 3Adenocarcinoma, Follicular 3Adenocarcinoma 3Uveal Melanoma 2Squamous Cell Carcinoma of Head and Neck 2Small Cell Lung Carcinoma 2Sarcoma 2

Interventions

Cyclophosphamide 115Dexamethasone 70fludarabine phosphate 57Cytarabine 56fludarabine 52Rituximab 51Peripheral Blood Stem Cell Transplantation 40Etoposide 40Gemcitabine 39Lenalidomide 38pembrolizumab 33Radiotherapy 33Busulfan 33Filgrastim 32Carboplatin 31Methotrexate 30Cyclosporine 29Cisplatin 29Bortezomib 29Mycophenolic Acid 28Melphalan 28venetoclax 27Paclitaxel 26Whole-Body Irradiation 24Antilymphocyte Serum 23Temozolomide 22Granulocyte Colony-Stimulating Factor 20Calcium Dobesilate 20Bevacizumab 20Tacrolimus 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
OTHER × Recurrence × lenvatinib × Clear all
NCT05263492 2025-10-02

Study of Lenvatinib w/ Pembro in Black Participants w/Mismatch Repair-Prof Recurrent Endometrial Cancer

Virginia Commonwealth University

Phase 2 Terminated
4 enrolled 8 charts
Gynecologic

Recurrence, Endometrial Neoplasms

NCT07077798 2025-07-22

Adjuvant Sintilimab Plus Lenvatinib for HCC Characterized With VETC Following Liver Resection

Tongji Hospital

Phase NA Not yet recruiting
234 enrolled
Gastrointestinal

Carcinoma, Hepatocellular, Recurrence

NCT06420440 2025-05-01

Neoadjuvant Therapy in Patients With Resectable HCC Screened by a Multimodal Deep Learning Model

Tongji Hospital

Phase 2 Recruiting
160 enrolled
Gastrointestinal

Carcinoma, Hepatocellular, Recurrence

NCT06253364 2024-03-13

VETC is an Effective Marker for Postoperative Adjuvant Immunotherapy

Tongji Hospital

Completed
462 enrolled

Recurrence

NCT05910970 2024-01-23

PREVENT-2

Guangxi Medical University

Phase 3 Unknown
200 enrolled
Gastrointestinal

Carcinoma, Hepatocellular, Recurrence

NCT05444478 2023-11-07

Microwave Ablation Simultaneously Combined With Lenavatinib for Recurrent Hepatocellular Carcinoma

Sun Yat-sen University

Phase NA Recruiting
274 enrolled
Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡